Activities and characteristics of transfer factors
This report summarizes three components of our transfer factor research program. Several clinical studies have used oral administration of transfer factor containing materials. Sceptics have rejected these findings by assuming that the acidic and enzymatic environment of the gastrointestinal tract would destroy the factors. To further examine this issue, we have conducted dose-response studies of the delayed-type hypersensitivity reaction in mice that were given transfer factor either by gavage or subcutaneously. There were no difference in the responses that were related to the route of administration. We conclude that oral route of administration is efficacious and should be used when possible.
We have also studied the effects of transfer factors on immune responses by recipients. The details of this research are presented in the paper by Dr. Alvarez-Thull. Briefly, the study showed that recipients of a specific transfer factor responded to the antigen for which the factor was specific by secreting gamma-IFN, but no other cytokines.
The structures of transfer factor molecules are unknown. We have developed a process for isolating transfer factors in pure form and we have obtained preliminary data concerning amino acid sequences. Our goal is to obtain the complete primary structure of several transfer factor molecules.
Hanks’ balanced salt solution
keyhole limpet hemocyanin
Unable to display preview. Download preview PDF.
- 1.Peterson EA, Greenberg LE, Manzara T, Rozzo SJ & Kirkpatrick CH. Selective removal of transfer factor activity with antigen. In: Immunobiology of Transfer Factor. New York: Academic Press, 1983: 65–74.Google Scholar
- 6.Dwyer JM: The use of antigen-specific transfer factor in the management of infections with herpes viruses. In: Immunobiology of Transfer Factor. New York: Academic Press, 1983: 233–43.Google Scholar
- 7.Viza D, Rosenfeld F, Phillips J, Vich JM, Denis J, Bonissent JF & Dogbe K. Specific bovine transfer factor for the treatment of herpes infections. In: Immunobiology of Transfer Factor. New York: Academic Press, 1983: 245–58.Google Scholar
- 8.Kirkpatrick CH & Greenberg LE. Treatment of chronic mucocutaneous candidiasis with transfer factor. In: Immunobiology of Transfer Factor. New York: Academic Press, 1983: 547–62.Google Scholar
- 9.Jeter WS, Kibler R & Stephens CAL. J Reticuloend Soc 1977; 22: 46a.Google Scholar
- 10.Jeter WS, Kibler R, Soli TC & Stephens CAL. Oral administration of bovine and human dialyzable transfer factor to human volunteers. In: Immune Regulators in Transfer Factor. New York: Academic Press, 1979: 452–58.Google Scholar
- 12.Viza D, Vich JM, Phillips J & Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985; 4: 27–30.Google Scholar
- 13.McMeeking A, Borkowski W, Klesius PH, Bonk S, Holzman RS & Lawrence HS. A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infec Dis 1990; 161: 108–12.Google Scholar
- 16.Jones JF, Schumacher MJ, Jeter WS & Hicks MJ. Oral-bovine transfer factor (OTF) use in the hyper-IgE syndrome. In: Immunobiology of Transfer Factor. New York: Academic Press, 1983: 261–70.Google Scholar
- 21.Burger DR, Wampler P, Vandenbark AA & Vetto RM. A structural model for human transfer factor suggested by enzymatic susceptibilities. In: Immune Regulators in Transfer Factors. New York: Academic Press, 1979: 377–85.Google Scholar
- 22.Wilson GB, Morin ML, Stuart LD, Williams AM, Floyd E, Paddock GV, Just L & Fudenberg HH. Transfer of cell-mediated immunity in vitro to human lymphocytes using dialyzable leukocyte extracts from immune burros. In: Immunobiology of Transfer Factor. New York: Academic Press, 1983: 213–29.Google Scholar